Kairos Pharma (NYSEAMERICAN:KAPA) Rating Lowered to “Hold” at Maxim Group

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) was downgraded by research analysts at Maxim Group from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, FinViz reports.

Kairos Pharma Stock Performance

KAPA traded up $0.01 during trading on Thursday, hitting $0.45. The stock had a trading volume of 32,476 shares, compared to its average volume of 215,930. The firm has a market capitalization of $1.54 million, a P/E ratio of -0.22 and a beta of 1.85. The company’s 50-day moving average price is $1.00 and its 200 day moving average price is $2.74. Kairos Pharma has a twelve month low of $0.38 and a twelve month high of $7.28.

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. As a group, equities analysts expect that Kairos Pharma will post -2.59 earnings per share for the current fiscal year.

About Kairos Pharma

(Get Free Report)

Kairos Pharma is a clinical-stage biopharmaceutical company focused on developing cancer treatments intended to address drug resistance and improve responses to therapy. The company’s research centers on mechanisms that can help tumors evade treatment. Its pipeline includes KROS-101, an investigational candidate designed to target leukemia inhibitory factor (LIF), a signaling pathway associated with cancer growth and treatment resistance. Kairos is also advancing other oncology research programs; its candidates remain investigational.

Further Reading

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.